Denali Therapeutics Statistics
Share Statistics
Denali Therapeutics has 143.92M shares outstanding. The number of shares has increased by 4.18% in one year.
Shares Outstanding | 143.92M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.39% |
Owned by Institutions (%) | n/a |
Shares Floating | 124.63M |
Failed to Deliver (FTD) Shares | 6.69K |
FTD / Avg. Volume | 0.82% |
Short Selling Information
The latest short interest is 7.43M, so 5.16% of the outstanding shares have been sold short.
Short Interest | 7.43M |
Short % of Shares Out | 5.16% |
Short % of Float | 5.96% |
Short Ratio (days to cover) | 11.35 |
Valuation Ratios
The PE ratio is -20.3 and the forward PE ratio is -10.87.
PE Ratio | -20.3 |
Forward PE | -10.87 |
PS Ratio | 8.92 |
Forward PS | 48 |
PB Ratio | 2.86 |
P/FCF Ratio | -7.95 |
PEG Ratio | n/a |
Enterprise Valuation
Denali Therapeutics Inc. has an Enterprise Value (EV) of 2.87B.
EV / Earnings | -19.78 |
EV / Sales | 8.69 |
EV / EBITDA | -15.96 |
EV / EBIT | -14.61 |
EV / FCF | -7.75 |
Financial Position
The company has a current ratio of 13.65, with a Debt / Equity ratio of 0.
Current Ratio | 13.65 |
Quick Ratio | 13.65 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -18.16%.
Return on Equity (ROE) | -0.14% |
Return on Assets (ROA) | -0.13% |
Return on Capital (ROIC) | -18.16% |
Revenue Per Employee | 847.52K |
Profits Per Employee | -372.37K |
Employee Count | 390 |
Asset Turnover | 0.29 |
Inventory Turnover | 0 |
Taxes
Income Tax | 30.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 0.09% in the last 52 weeks. The beta is 1.39, so Denali Therapeutics 's price volatility has been higher than the market average.
Beta | 1.39 |
52-Week Price Change | 0.09% |
50-Day Moving Average | 26.45 |
200-Day Moving Average | 23.03 |
Relative Strength Index (RSI) | 38.84 |
Average Volume (20 Days) | 817.87K |
Income Statement
In the last 12 months, Denali Therapeutics had revenue of $330.53M and earned -$145.22M in profits. Earnings per share was $-1.06.
Revenue | 330.53M |
Gross Profit | 313.81M |
Operating Income | -196.70M |
Net Income | -145.22M |
EBITDA | -179.97M |
EBIT | -196.70M |
Earnings Per Share (EPS) | -1.06 |
Balance Sheet
The company has $127.11M in cash and $52.24M in debt, giving a net cash position of $74.86M.
Cash & Cash Equivalents | 127.11M |
Total Debt | 52.24M |
Net Cash | 74.86M |
Retained Earnings | -1.12B |
Total Assets | 1.45B |
Working Capital | 781.75M |
Cash Flow
In the last 12 months, operating cash flow was -$357.99M and capital expenditures -$12.94M, giving a free cash flow of -$370.93M.
Operating Cash Flow | -357.99M |
Capital Expenditures | -12.94M |
Free Cash Flow | -370.93M |
FCF Per Share | -2.7 |
Margins
Gross margin is 94.94%, with operating and profit margins of -59.51% and -43.94%.
Gross Margin | 94.94% |
Operating Margin | -59.51% |
Pretax Margin | -43.93% |
Profit Margin | -43.94% |
EBITDA Margin | -54.45% |
EBIT Margin | -59.51% |
FCF Margin | -112.22% |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -4.62% |
FCF Yield | -11.23% |
Analyst Forecast
The average price target for DNLI is $32, which is 39.4% higher than the current price. The consensus rating is "Buy".
Price Target | $32 |
Price Target Difference | 39.4% |
Analyst Consensus | Buy |
Analyst Count | 11 |
Scores
Altman Z-Score | 12.87 |
Piotroski F-Score | 2 |